A-204 Associations between Apolipoprotein B/A1 Ratio, Lipoprotein(a) and the Risk of Metabolic-associated Fatty liver Diseases in a Korean Population

Abstract

Abstract Background Metabolic-associated fatty liver disease (MAFLD) is a new nomenclature of the fatty liver condition associated with metabolic dysfunction. Little study regarding the association between apolipoprotein and lipoprotein(a) and MAFLD has been performed. This study aimed to investigate the association between apolipoprotein B/A1 ratio (apo B/A1), lipoprotein(a), and MAFLD based on new diagnostic criteria in a Korean population. Methods This cross-sectional study consisted of 14 420 consecutive adults underwent abdominal ultrasonography among the general Korean population visiting at comprehensive health promotion center in Samsung Changwon Hospital from January 2021 to December 2021. Clinical data, anthropometric and biochemical parameters were reviewed. According to the Asian Pacific Association for the Study of Liver guideline, the MAFLD was diagnosed based on hepatic steatosis by abdominal ultrasonography and the presence of overweight/obesity, type 2 diabetes, or the evidence of metabolic dysregulation. Multivariate logistic regression was conducted to analyze the independent association between apo B/A1 ratio and MAFLD. Results The prevalence of MAFLD in the general Korean population was 34.5% (4978/14 420). Multivariate logistic regression analysis revealed that Apo B/A1 ratio (odds ratio: 3.913, P = 0.019) was independently associated with the MAFLD. Lipoprotein(a) levels are inversely associated with the MAFLD, especially in subjects with hepatic fibrosis (P < 0.0001). Conclusion Apo B/A1 ratio and lipoprotein(a) have opposite association with the MAFLD in a Korean population. This study suggests that apo B/A1 ratio could be useful biomarkers for MALFD, while lipoprotein(a) should be used with caution as a predictive biomarker for MAFLD.